国产乱色精品成人免费视频,国产婷婷色一区二区三区在线,八戒八戒午夜视频,国内精品视频一区二区三区八戒

加拿大Resverlogix  
Resverlogix Corp. (TSX: RVX) 是一家心血管疾病臨床研究公司，公司擁有能夠調(diào)節(jié)蛋白質(zhì)形成的表觀遺傳學平臺技術(shù)。Resverlogix 正在開發(fā) RVX-208——用于治療動脈粥樣硬化的同類首個小分子。RVX-208 是首個正在進行臨床試驗的 BET 溴區(qū)結(jié)構(gòu)域抑制劑。出自 Resverlogix 表觀遺傳學藥物發(fā)現(xiàn)平臺的新復合制劑通過抑制 BET 溴區(qū)結(jié)構(gòu)域而發(fā)揮作用，并有希望用來治療癌癥、自身免疫性疾病和神經(jīng)退行性疾病等多種病癥。Resverlogix 的普通股在多倫多證券交易所交易 (TSX: RVX)。

Resverlogix Corp. is a publicly traded biotechnology company (TSX:RVX) engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas? Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases.

Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.